# Narcolepsy Type 1 FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/narcolepsy-type-1

> 8 upcoming FDA catalysts in narcolepsy Type 1: alks 2680 dose 1 (ALKS) on May 2027 (primary completion); alks 2680 dose 1 (ALKS) on May to Aug 2027 (topline data readout); alks 2680 dose 1 (ALKS) on June 2027 (primary completion); alks 2680 dose 1 (ALKS) on Jun to Sep 2027 (topline data readout); and 4 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| June 3, 2025 | [ORZEYFUL (oveporexton) primary completion](https://sec-api.dev/pdufa/oveporexton) | TAK | Narcolepsy Type 1 | completed | "NCT06470828 (A Study of TAK-861 for the Treatment of Narcolepsy Type 1): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-03 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2026-08-31." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06470828)) |
| June 4, 2025 | [TAK-861 primary completion](https://sec-api.dev/pdufa/tak-861) | TAK | Narcolepsy Type 1 | completed | "NCT06505031 (A Study of TAK-861 in People With Narcolepsy Type 1): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-04 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2026-07-16." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06505031)) |
| June 19, 2025 | [Alks 2680 dose 1 primary completion](https://sec-api.dev/pdufa/alks-2680) | ALKS | Narcolepsy Type 1 | completed | "NCT06358950 (A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-19 (ACTUAL); Lead Sponsor Alkermes, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06358950)) |
| July 21, 2025 | [Neuropeptide topline data readout](https://sec-api.dev/pdufa/neuropeptide) | ALKS | narcolepsy type 1 | completed, positive | "DUBLIN, July 21, 2025 -- Alkermes plc (Nasdaq: ALKS) today announced positive topline results from the randomized double-blind treatment period of the Vibrance-1 phase 2 study evaluating alixorexton in patients with narcolepsy type 1 (NT1)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1520262/000095017025097323/alks-ex99_1.htm)) |
| July 16, 2026 | [TAK-861 topline data readout](https://sec-api.dev/pdufa/tak-861) | TAK | Narcolepsy Type 1 | completed | "NCT06505031 (A Study of TAK-861 in People With Narcolepsy Type 1): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-04 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2026-07-16." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06505031?tab=results)) |
| August 31, 2026 | [ORZEYFUL (oveporexton) topline data readout](https://sec-api.dev/pdufa/oveporexton) | TAK | Narcolepsy Type 1 | completed | "NCT06470828 (A Study of TAK-861 for the Treatment of Narcolepsy Type 1): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-03 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2026-08-31." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06470828?tab=results)) |
| May 2027 | [Alks 2680 dose 1 primary completion](https://sec-api.dev/pdufa/alks-2680) | ALKS | Narcolepsy Type 1 | scheduled | "NCT07455383 (A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-05 (ESTIMATED); Lead Sponsor Alkermes, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07455383)) |
| May to Aug 2027 | [Alks 2680 dose 1 topline data readout](https://sec-api.dev/pdufa/alks-2680) | ALKS | Narcolepsy Type 1 | scheduled | "NCT07455383 (A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-05 (ESTIMATED); Lead Sponsor Alkermes, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07455383)) |
| June 2027 | [Alks 2680 dose 1 primary completion](https://sec-api.dev/pdufa/alks-2680) | ALKS | Narcolepsy Type 1 | scheduled | "NCT07540897 (A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Alkermes, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07540897)) |
| Jun to Sep 2027 | [Alks 2680 dose 1 topline data readout](https://sec-api.dev/pdufa/alks-2680) | ALKS | Narcolepsy Type 1 | scheduled | "NCT07540897 (A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Alkermes, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07540897)) |
| Nov 2027 to Feb 2028 | [TAK-360 topline data readout](https://sec-api.dev/pdufa/tak-360) | TAK | Narcolepsy Type 1 | scheduled | "NCT07633301 (A Study of TAK-360 in Adults With Narcolepsy Type 1 (Narcolepsy With Cataplexy)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-11-28 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07633301)) |
| November 2027 | [TAK-360 primary completion](https://sec-api.dev/pdufa/tak-360) | TAK | Narcolepsy Type 1 | scheduled | "NCT07633301 (A Study of TAK-360 in Adults With Narcolepsy Type 1 (Narcolepsy With Cataplexy)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-11-28 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07633301)) |
| Feb to May 2028 | [TAK-861 topline data readout](https://sec-api.dev/pdufa/tak-861) | TAK | Narcolepsy Type 1 | scheduled | "NCT05816382 (A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-02-28 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05816382)) |
| February 2028 | [TAK-861 primary completion](https://sec-api.dev/pdufa/tak-861) | TAK | Narcolepsy Type 1 | scheduled | "NCT05816382 (A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-02-28 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05816382)) |

## Drugs

- [ORZEYFUL (oveporexton)](https://sec-api.dev/pdufa/oveporexton) (TAK)
- [TAK-861](https://sec-api.dev/pdufa/tak-861) (TAK)
- [Alks 2680 dose 1](https://sec-api.dev/pdufa/alks-2680) (ALKS)
- [Neuropeptide](https://sec-api.dev/pdufa/neuropeptide) (ALKS)
- [TAK-360](https://sec-api.dev/pdufa/tak-360) (TAK)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/narcolepsy-type-1.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Narcolepsy Type 1 FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/narcolepsy-type-1

```bibtex
@misc{secapidev_indications_narcolepsy_type_1_20261116,
  title        = {Narcolepsy Type 1 FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/narcolepsy-type-1}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_narcolepsy_type_1_20261116","title":"Narcolepsy Type 1 FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/narcolepsy-type-1","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
